Nan Wang1, DaFu Yang1, Bin Ji1, JianYou Li2. 1. Medical Department, Huzhou Traditional Chinese Medicine Hospital, People's Republic of China. 2. Medical Department, Huzhou Central Hospital, People's Republic of China lijianyou120@126.com.
Abstract
OBJECTIVE: Angiotensin-converting enzyme (ACE) I/D polymorphism has been reported to be associated with lung cancer, but the results of previous studies are conflicting. The present study was designed to investigate the association between this polymorphism and the risk of lung cancer using a meta-analysis of the published studies. METHODS: Two investigators independently searched the PubMed, Embase and CNKI databases. This meta-analysis covered six case-control studies, including 807 lung cancer patients and 816 healthy controls. RESULTS: The results of this meta-analysis based on all the studies showed no significant association between ACE I/D gene polymorphism and lung cancer risk (DD vs II: OR = 1.18, 95% CI = 0.68-2.04; DI vs II: OR = 0.93, 95% CI = 0.56-1.53; DD+DI vs II: OR = 1.01, 95% CI = 0.68-1.50; DD vs II+DD: OR =1.11, 95% CI = 0.73-1.71). In the subgroup analysis by race and the larger studies (n > 200 participants), no significant associations between the ACE I/D polymorphism and risk of lung cancer were indicated. However, when the analyses were restricted to small studies (n ≤ 200 participants), a significantly higher risk was observed (DD vs II: OR = 2.57, 95% CI = 1.24-5.30). CONCLUSIONS: This meta-analysis suggests that the ACE gene I/D polymorphism may not be associated with the risk of lung cancer, and the observed increase in the risk of lung cancer may be due to small-study bias.
OBJECTIVE:Angiotensin-converting enzyme (ACE) I/D polymorphism has been reported to be associated with lung cancer, but the results of previous studies are conflicting. The present study was designed to investigate the association between this polymorphism and the risk of lung cancer using a meta-analysis of the published studies. METHODS: Two investigators independently searched the PubMed, Embase and CNKI databases. This meta-analysis covered six case-control studies, including 807 lung cancerpatients and 816 healthy controls. RESULTS: The results of this meta-analysis based on all the studies showed no significant association between ACE I/D gene polymorphism and lung cancer risk (DD vs II: OR = 1.18, 95% CI = 0.68-2.04; DI vs II: OR = 0.93, 95% CI = 0.56-1.53; DD+DI vs II: OR = 1.01, 95% CI = 0.68-1.50; DD vs II+DD: OR =1.11, 95% CI = 0.73-1.71). In the subgroup analysis by race and the larger studies (n > 200 participants), no significant associations between the ACE I/D polymorphism and risk of lung cancer were indicated. However, when the analyses were restricted to small studies (n ≤ 200 participants), a significantly higher risk was observed (DD vs II: OR = 2.57, 95% CI = 1.24-5.30). CONCLUSIONS: This meta-analysis suggests that the ACE gene I/D polymorphism may not be associated with the risk of lung cancer, and the observed increase in the risk of lung cancer may be due to small-study bias.
Authors: Danial Mehranfard; Gabriela Perez; Andres Rodriguez; Julia M Ladna; Christopher T Neagra; Benjamin Goldstein; Timothy Carroll; Alice Tran; Malav Trivedi; Robert C Speth Journal: J Renin Angiotensin Aldosterone Syst Date: 2021-07-05 Impact factor: 1.636
Authors: Asmahan A El Ezzi; Jordan M Clawson; Mohammed A El-Saidi; Wissam R Zaidan; Abigail Kovash; Jeremy Orellana; AnnaKarina Thornock; Ruhul H Kuddus Journal: Prostate Cancer Date: 2020-02-07